Salivary biomarker testing represents a minimally invasive approach to detecting molecular signatures of corticobasal syndrome (CBS) and progressive supranuclear palsy (PSP). Unlike cerebrospinal fluid (CSF) collection which requires lumbar puncture, saliva can be collected safely and repeatedly, enabling longitudinal monitoring and large-scale screening programs.
CBS and PSP are 4R-tauopathies characterized by intracellular accumulation of hyperphosphorylated tau protein in neurons and glia. The neurodegenerative process releases various biomarkers into peripheral fluids, including:
- Neurofilament light chain (NfL): Marker of neuroaxonal damage
- Phosphorylated tau (p-tau181, p-tau217): Specific to tau pathology
- Alpha-synuclein: Relevant for differential diagnosis from Parkinson's disease
- Cortisol: Indicator of hypothalamic-pituitary-adrenal axis dysregulation
- Total protein and inflammatory markers: Reflect neuroinflammation
Salivary glands are innervated by autonomic fibers and may reflect CNS pathology through:
- Direct drainage of inflammatory mediators
- Neuronal transsynaptic transport
- Peripheral immune cell infiltration
¶ Standard Saliva Collection
| Method |
Protocol |
Advantages |
| Passive drool |
Expectorate into sterile tube |
Simple, no devices needed |
| Salivette® |
Cotton roll in absorbent device |
Standardized collection |
| microfluidic device |
Automated collection |
Volume control, reduced contamination |
Pre-collection protocol:
- Fast for 30 minutes
- Rinse mouth with water
- Avoid smoking, coffee, brushing teeth
- Collect in morning hours when possible
- Centrifuge at 2,000 × g for 10 minutes within 30 minutes
- Store supernatant at -80°C
- Avoid repeated freeze-thaw cycles
- Note collection time for cortisol normalization
NfL is released during axonal damage and is elevated in various neurodegenerative conditions. Salivary NfL shows moderate correlation with CSF NfL, though concentrations are approximately 100-fold lower.
Key findings:
- Elevated in CBS compared to healthy controls
- Higher levels in PSP than CBS in some cohorts
- Correlates with disease severity and progression rate
- Potential for distinguishing CBS from AD
Phosphorylated tau species are disease-specific biomarkers. Salivary p-tau detection remains technically challenging due to low concentrations.
Current evidence:
- p-tau181 detectable in saliva using ultrasensitive immunoassays (SIMOA)
- Higher in CBS/PSP than controls
- p-tau217 shows higher diagnostic accuracy than p-tau181
- More studies needed for validation
Alpha-synuclein pathology can be assessed through seed amplification assays applied to salivary samples.
Diagnostic potential:
- Real-time quaking-induced conversion (RT-QuIC) detects pathological α-synuclein
- Sensitivity lower than CSF or skin biopsy
- Useful for excluding CBS mimics (PD, MSA)
- Asymmetric presentation in CBS may reflect in salivary findings
¶ Cortisol and Stress Biomarkers
HPA axis dysfunction is documented in CBS/PSP.
Findings:
- Elevated basal cortisol in CBS/PSP
- Altered diurnal cortisol rhythm
- Correlates with frontal lobe dysfunction
- Salivary cortisol collection enables multiple daily sampling
Emerging studies use multiplex platforms to measure multiple biomarkers simultaneously:
- NfL + p-tau181 + α-synuclein: Combines neurodegeneration, tau, and synuclein markers
- Inflammatory panel: IL-6, TNF-α, IL-1β
- Oxidative stress markers: 8-OHdG, isoprostanes
Salivary biomarkers show differential patterns:
| Biomarker |
CBS |
PSP |
PD |
HC |
| NfL |
↑↑ |
↑↑↑ |
↑ |
- |
| p-tau181 |
↑ |
↑↑ |
- |
- |
| p-tau217 |
↑ |
↑↑ |
- |
- |
| α-synuclein (seed) |
± |
± |
+++ |
- |
| Cortisol |
↑ |
↑↑ |
↑ |
- |
Key differentiators:
- CBS shows moderate NfL elevation, lower than PSP
- PSP has highest p-tau and cortisol levels
- PD has prominent α-synuclein seeding activity
- Combined panel improves diagnostic accuracy
| Source |
Invasiveness |
NfL |
p-tau |
α-syn |
Accessibility |
| CSF |
High (LP) |
+++ |
+++ |
+++ |
Low |
| Blood |
Low |
++ |
++ |
++ |
High |
| Saliva |
Minimal |
+ |
+ |
+ |
Highest |
| Skin biopsy |
Moderate |
N/A |
N/A |
+++ |
Moderate |
Advantages of saliva:
- Non-invasive collection
- No specialized personnel required
- Enables home collection
- Suitable for repeated sampling
Limitations:
- Lower biomarker concentrations
- Variable flow rate affecting dilution
- Oral cavity contamination
- Less validated than CSF/blood
Salivary biomarker testing for CBS/PSP remains research-oriented with no validated clinical assay. However, implementation pathways are emerging:
- Screening settings: At-risk individuals, prodromal detection
- Differential diagnosis: Supporting clinical assessment
- Disease monitoring: Tracking progression, treatment response
- Clinical trials: Enrollment criteria, pharmacodynamic markers
- Ultrasensitive immunoassay platforms (SIMOA, Single Molecule Array)
- Standardized collection protocols
- Reference ranges from large control cohorts
- Quality control procedures
- Cost: Similar to blood-based testing, lower than CSF
- Turnaround: 1-2 weeks depending on assay
- Interpretation: Require neurological context
- Insurance: Generally not covered for neurodegenerative indications
- Exosome isolation: Enriching neuronal-derived exosomes improves biomarker detection
- MicroRNA panels: Salivary miRNA signatures for CBS/PSP
- Proteomics: Unbiased discovery of novel salivary markers
- Machine learning: Multi-analyte algorithms for diagnosis
- Large prospective cohorts with clinically confirmed CBS
- Standardized assays across laboratories
- Correlation with imaging and clinical progression
- Cut-off values for clinical use
- Salivary neurofilament light chain in Parkinson's disease and atypical parkinsonisms
- Salivary biomarkers for Alzheimer's disease and Parkinson's disease: A systematic review
- p-tau181 and p-tau217 in blood and saliva as biomarkers for neurodegenerative diseases
- Salivary alpha-synuclein RT-QuIC in Parkinson's disease diagnosis
- Cortisol dysregulation in progressive supranuclear palsy and corticobasal syndrome
- Salivary inflammatory markers in neurodegenerative diseases
- Minimally invasive biomarkers for tauopathies: Blood and beyond
- Fluid biomarker profiles in corticobasal syndrome and progressive supranuclear palsy
- Salivary extracellular vesicles as a source of neurodegenerative disease biomarkers
- Comparative analysis of fluid biomarkers in atypical parkinsonism